Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients

International Journal of Neuropsychopharmacology

Volumn 11, Issue 5, 2008, Pages 679-684

  Vik Mo, Audun O ^a,b   Birkenaes, Astrid B ^c,d   Fernø, Johan ^a,b   Jonsdottir, Halldora ^c,d   Andreassen, Ole A ^c,d   Steen, Vidar M ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Atypical antipsychotics; Dyslipidaemia; Gene expression; Schizophrenia; SREBP

Indexed keywords

ACYL COENZYME A DESATURASE; FATTY ACID SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INDUCTION; FASN GENE; FEMALE; GENE; GENE INDUCTION; HUMAN; HUMAN TISSUE; LIPOGENESIS; MALE; MONOTHERAPY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCD GENE; SCHIZOPHRENIA; TRANSCRIPTION REGULATION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD CELLS; CASE-CONTROL STUDIES; FATTY ACID SYNTHETASE COMPLEX; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; STEAROYL-COA DESATURASE; UP-REGULATION;

EID: 46449138724     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708008468     Document Type: Article

References (23)

1. Allison DB, Casey DE (2001). Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry 62 (Suppl. 7), 22-31.
2. Birkenaes AB, Opjordsmoen S, Brunborg C, Engh JA, Jonsdottir H, Ringen PA, Simonsen C, Vaskinn A, Birkeland KI, Friis S, Sundet K, Andreassen OA (2007). The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. Journal of Clinical Psychiatry 68, 917-923.
3. Birkenaes AB, Sogaard AJ, Engh JA, Jonsdottir H, Ringen PA, Vaskinn A, Friis S, Sundet K, Opjordsmoen S, Andreassen OA (2006). Sociodemographic characteristics and cardiovascular risk factors in patients with severe mental disorders compared with the general population. Journal of Clinical Psychiatry 67, 425-433.
4. Brown S (1997). Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry 171, 502-508.
5. Consensus Statement (American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity) (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27, 596-601.
6. Craig WY, Palomaki GE, Haddow JE (1989). Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. British Medical Journal 298, 784-788.
7. Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, Breilid H, Lovlie R, Berge RK, Stansberg C, Steen VM (2005). Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics Journal 5, 298-304.
8. Ferno J, Skrede S, Vik-Mo AO, Havik B, Steen VM (2006). Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neuroscience 7, 69.
9. Henderson DC (2005). Schizophrenia and comorbid metabolic disorders. Journal of Clinical Psychiatry 66 (Suppl. 6), 11-20.
10. Hulver MW, Berggren JR, Carper MJ, Miyazaki M, Ntambi JM, Hoffman EP, Thyfault JP, Stevens R, Dohm GL, Houmard JA, Muoio DM (2005). Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metabolism 2, 251-261.
11. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR (2007). Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Molecular Psychiatry 12, 934-945.
12. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007). From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proceedings of the National Academy of Sciences USA 104, 3456-3459.
13. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28, 519-526.
14. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, Tang W, Wiener K, Dvorin S, Dietz MB (2006). Prevalence of the metabolic syndrome among patients receiving clozapine. American Journal of Psychiatry 163, 1273-1276.
15. Ma J, Dempsey AA, Stamatiou D, Marshall KW, Liew CC (2006). Identifying leukocyte gene expression patterns associated with plasma lipid levels in human subjects. Atherosclerosis 191, 63-71.
16. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, et al. (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161, 1334-1349.
17. Matsui-Sakata A, Ohtani H, Sawada Y (2005). Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug metabolism and pharmacokinetics 20, 368-378.
18. Minet-Ringuet J, Even PC, Valet P, Carpéné C, Visentin V, Prévot D, Daviaud D, Quignard-Boulange A, Tomé D, de Beaurepaire R (2007). Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Molecular Psychiatry 12, 562-571.
19. Nasrallah HA (2006). Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrums 11 (Suppl. 7), 32-39.
20. Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, Yandell BS, Song Y, Cohen P, Friedman JM, Attie AD (2002). Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proceedings of the National Academy of Sciences USA 99, 11482-11486.
21. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB (2007). Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Archives of General Psychiatry 64, 242-249.
22. Raeder MB, Ferno J, Vik-Mo AO, Steen VM (2006). SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Molecular and cellular biochemistry 289, 167-173.
23. Smith RC, Lindenmayer JP, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A (2005). Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. International Journal of Neuropsychopharmacology 8, 183-194.